证券代码：300318 证券简称：博晖创新 公告编号：临 2025-012 北京博晖创新生物技术集团股份有限公司 关于计提资产减值准备及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 4 月 25 日召开第八届董事会第十次会议和第八届监事会第九次会议， 审议通过了《关于计提资产减值准备及核销资产的议案》，同意计提资产减值准 备及核销资产，其中，计提资产减值准备合计金额人民币 7,816,393.21 元；核销 资产合计金额人民币 3,781,057.71 元。现将具体情况公告如下： 一、本次计提资产减值准备基本情况 （一）本次计提资产减值准备概况 1、本次计提资产减值准备的原因 为真实反映公司财务状况和经营成果，公司依据《企业会计准则第8号—资 产减值》规定，基于谨慎性原则，对2024年公司及合并范围内各下属公司所属 资产进行了减值测试，判断存在减值的迹象，确定了需要计提减值准备的资产 项目。 2、本次计提资产减值准备的范围和金额 公司及下属子公司2024 ...

关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创 新"）于 2025 年 4 月 25 日召开第八届董事会第十次会议，审议通过了《关于召 开 2024 年度股东大会的议案》，现就相关事项公告如下： 一、召开会议的基本情况 （一）股东大会届次：2024 年度股东大会。 （二）股东大会的召集人：公司董事会。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律法规、 深圳证券交易所业务规则和公司章程等的规定。 （四）会议召开的日期、时间： 证券代码：300318 证券简称：博晖创新 公告编号：临 2025-018 北京博晖创新生物技术集团股份有限公司 1、现场会议时间：2025 年 5 月 20 日（星期二）14:00 开始 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 20 日 9:15-9:25，9:30-11:30 和 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：202 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-008 第八届监事会第九次会议决议公告 北京博晖创新生物技术集团股份有限公司 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第九次会议于 2025 年 4 月 25 日在公司会议室召开，会议通知于 2025 年 4 月 15 日以专人送达、邮件通知或电话通知的方式送达公司监事，会议由公司监事 会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议应出 席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和《公 司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2024 年度监事会工作报告》 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年度监事会工作报告》。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 本议案尚需提交公司股东大会审议。 2、审议通过《2024 年度财务决算报告》 具体内容详见公司于同日在巨潮资讯网（www.cnin ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-007 北京博晖创新生物技术集团股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第十次会议于 2025 年 4 月 25 日在公司会议室召开，会议通知于 2025 年 4 月 15 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议由公司董 事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次会议应出席 董事 7 人，实际出席董事 7 人，监事人员及高级管理人员列席了会议。本次会议的 召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2024 年度董事会工作报告》 《2024 年度董事会工作报告》详见巨潮资讯网（www.cninfo.com.cn）。 表决结果：7 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 本议案尚需提交公司股东大会审 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-010 北京博晖创新生物技术集团股份有限公司 2024 年度利润分配预案的公告 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 4 月 23 日召开第八届董事会第二次独立董事专门会议；于 2025 年 4 月 25 日召开第八届董事会第十次会议和第八届监事会第九次会议，审议通过了 《2024 年度利润分配预案》。 1、独立董事专门会议意见 独立董事认为：董事会提出的利润分配预案从公司的实际情况出发，符合公 司未来经营发展的需要，不存在损害投资者利益的情形，同意将该方案提交董事 会审议。 2、董事会意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度拟不派发现金红利，不送红股，不以资本公积金转增股 本。 董事会认为，公司 2024 年度利润分配预案综合考虑了公司 2025 年的经营计 划和 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-011 北京博晖创新生物技术集团股份有限公司 关于提请股东大会授权董事会 办理以简易程序向特定对象发行股票相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 4 月 25 日召开第八届董事会第十次会议，审议通过《关于提请股东大 会授权董事会办理以简易程序向特定对象发行股票相关事宜的议案》。 根据《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）、 《深圳证券交易所上市公司证券发行上市审核规则》（以下简称"《审核规则》"）、 《深圳证券交易所上市公司证券发行与承销业务实施细则》（以下简称"《实施 细则》"）及《公司章程》等相关规定，公司董事会提请股东大会授权董事会向 特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的 股票，授权期限为 2024 年度股东大会通过之日起至 2025 年度股东大会召开之日 止。上述事项尚需提交 2024 年度股东大会审议。具体 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 杜江涛 | 31881.14 | 39.92 | 不变 | | 郝虹 | 10281.00 | 12.87 | 不变 | | 梅迎军 | 2539.87 | 3.18 | 不变 | | 杨奇 | 1843.06 | 2.31 | -210.44 | | 陆洋 | 973.00 | 1.22 | 473.00 | | 何晓雨 | 695.98 | 0.87 | 不变 | | 杜江虹 | 611.96 | 0.77 | 不变 | | 顾春宇 | 440.01 | 0.55 | 不变 | | 刘合普 | 273.62 | 0.34 | -10.00 | | 刘彩玲 | 270.00 | 0.34 | 新进 | | | 较上个报告期退出前十大股东有 | | | | 香港中央结算有限公司 | 547.16 | 0.69 | 退出 | | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- ...

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 0 RMB per 10 shares and no bonus shares, based on a total of 816,900,495 shares[3]. - The company's operating revenue for 2024 was ¥851,694,578.15, a decrease of 18.53% compared to ¥1,045,429,099.92 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥9,245,978.84, representing a significant increase of 137.09% from a loss of ¥24,929,391.08 in 2023[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,329,787.16, up 144.58% from a loss of ¥27,657,660.92 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥38,691,051.23, a decline of 128.24% compared to ¥137,017,197.71 in 2023[20]. - The total assets at the end of 2024 were ¥4,125,558,100.42, an increase of 5.08% from ¥3,926,015,273.52 at the end of 2023[20]. - The net assets attributable to shareholders at the end of 2024 were ¥1,378,686,990.40, a slight increase of 0.67% from ¥1,369,538,542.38 at the end of 2023[20]. - The company reported a total revenue of ¥576.92 million from biological products, with a gross margin of 42.46%, down 20.50% year-over-year[88]. - The revenue from the biological products segment was ¥576,922,488.10, accounting for 67.74% of total revenue, down 20.50% from ¥725,659,469.73 in the previous year[84]. Market Overview - The company operates in the in-vitro diagnostic (IVD) industry, which is crucial for clinical diagnosis and has a global market size of $81 billion in 2024, down 30% year-on-year[32]. - The Chinese in vitro diagnostic market is expected to reach nearly 120 billion RMB in 2024, remaining stable compared to 2023, with local brand products accounting for approximately 50%[34]. - The in vitro diagnostic market in China is projected to grow at a compound annual growth rate (CAGR) of 5-8% over the next five years, potentially reaching around 165 billion RMB by 2029[34]. - The blood products market in China is expected to reach 60 billion RMB by 2024, with a projected growth to 78 billion RMB by 2027, reflecting a CAGR of 11.6% from 2022 to 2027[41]. - The global blood products market is anticipated to exceed 93.1 billion USD by 2030, maintaining a CAGR of approximately 10%[40]. Product Development and Innovation - The company is focused on technological innovation in the life sciences sector, particularly in the fields of testing instruments and biological products[30]. - The company is developing a quantum dot fluorescence immunoassay analyzer, which will be compatible with various diagnostic kits, scheduled for launch in May 2026[58]. - The company is also set to release multiple allergen-specific IgE antibody testing kits by July 2027, targeting various environmental and food allergens[58]. - The company reported a significant increase in R&D investment, focusing on innovative diagnostic technologies and expanding its product portfolio[59]. - The company is actively pursuing regulatory approvals to support its growth strategy in the biopharmaceutical market[69]. Regulatory Compliance and Governance - The financial report has been confirmed as true, accurate, and complete by the company's management, including the CEO and accounting heads[3]. - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and maintaining a clear governance structure[148]. - The company has established a robust investor relations management system, fostering good interactions with investors[156]. - The company has a complete and independent financial accounting system, ensuring financial decisions are made independently[162]. - The company respects the rights of stakeholders, including banks, employees, suppliers, and customers, promoting sustainable development[155]. Strategic Initiatives - The company aims to enhance its core competitive advantages and improve operational efficiency through product research and innovation, as well as marketing capability development[125]. - The company plans to focus on the medical health industry, emphasizing both internal growth and external expansion strategies[125]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals[7]. - The company is committed to maintaining high-quality standards in its diagnostic products, ensuring compliance with regulatory requirements[59]. - The company aims to optimize its supply chain and diversify sales channels in response to the significant price reductions in HPV products due to centralized procurement initiatives starting in 2024[130]. Human Resources and Talent Development - The total number of employees at the end of the reporting period is 2,179, with 252 in the parent company and 1,927 in major subsidiaries[195]. - The employee composition includes 1,117 technical personnel, 487 production personnel, and 218 sales personnel, indicating a strong focus on technical expertise[195]. - The company emphasizes a competitive and performance-oriented compensation policy to attract and retain high-performing employees[197]. - The training program includes a three-tier talent pool covering core business units, ensuring a strong talent pipeline for sustainable development[198]. - The company has 16 employees with a doctoral degree and 73 with a master's degree, reflecting a highly educated workforce[195].

Investment Rating - The industry investment rating is "Outperform the Market - A" [4] Core Viewpoints - The report highlights a steady growth in domestic albumin batch approvals, with a 12% year-on-year increase in Q1 2025, while imported albumin saw a 9% decline [9][10] - The report suggests a long-term growth potential in the immunoglobulin market, with a 15% year-on-year increase in intravenous immunoglobulin (IVIG) approvals in Q1 2025 [18][24] - The report identifies key companies to watch, including Tian Tan Biological, Pai Lin Biological, Bo Ya Biological, Shanghai Lai Shi, and Hua Lan Biological [3] Summary by Sections 1. Overview of Blood Product Batch Approvals in Q1 2025 - Domestic albumin approvals reached 418 batches, up 12% year-on-year, while imported albumin approvals totaled 778 batches, down 9% [9][10] - Intravenous immunoglobulin (IVIG) approvals were 324 batches, up 15%, and intramuscular immunoglobulin (IMIG) approvals were 9 batches, up 13% [9] - For specific immunoglobulins, hepatitis B immunoglobulin approvals were 11 batches (up 83%), tetanus immunoglobulin 35 batches (up 13%), and rabies immunoglobulin 34 batches (up 42%) [9] 2. Albumin Analysis - The report notes a compound annual growth rate (CAGR) of 11.4% for albumin approvals from 2011 to 2024, with domestic albumin growing at 5.9% and imported at 16.7% [11] - In Q1 2025, the total albumin approvals were 1196 batches, reflecting a slight decline of 2.4% year-on-year [11] 3. Immunoglobulin Analysis - The report indicates a CAGR of 8.4% for IVIG approvals from 2011 to 2024, with Q1 2025 showing 324 batches approved [18] - The leading companies in the IVIG market accounted for approximately 61% of the market share in Q1 2025 [24] 4. Special Immunoglobulins - The report highlights significant growth in specific immunoglobulin approvals, particularly for hepatitis B and rabies, with notable increases in batch approvals [28][29] - The market for tetanus immunoglobulin is also growing, with a 13% increase in approvals [28] 5. Coagulation Factor Analysis - The report notes a CAGR of 13.6% for human coagulation factor VIII approvals from 2011 to 2024, with Q1 2025 approvals at 163 batches, up 12% [35] - Prothrombin complex concentrate (PCC) approvals increased by 26% year-on-year, totaling 82 batches in Q1 2025 [35] - The report identifies leading companies in the coagulation factor market, which hold significant market shares [43]

内容概要：人血清白蛋白（Human Serum Albumin，HSA）是血液或血浆中主要蛋白成分，由肝脏细胞 生产，占血浆总蛋白的 60%，对维持血浆渗透压、保持血管内外液体平衡具有重要的作用。近些年 来，我国65岁及以上人口和占比持续提升，全国老龄化进程不断加速，叠加国内经济不断发展、临床用 药日益普及，以及医生、患者对血液制品认识持续提升，使得我国在术后或免疫力低的情况下需要使用 血液制品的患者将越来越多，带来人血清白蛋白市场扩容。据统计，2024年我国人血清白蛋白治疗药物 市场规模已从2018年的189亿元增长至395亿元，根据市场预测，2030年有望达到5701亿元以上。 相关上市企业：天坛生物（600161）；上海莱士（002252）；华兰生物（002007）；派林生物 （000403）；卫光生物（002880）；博晖创新（300318）等 相关企业：华通福源生物技术（北京）股份有限公司；深圳普罗吉医药科技有限公司；武汉禾元生物科 技股份有限公司；河北华凯惠合生物医药有限公司；无锡和邦生物科技有限公司等 关键词：产业链；人血清白蛋白治疗药物市场规模；非药用人血清白蛋白市场规模；竞争格局；重点企 业 ...